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Abstract A variety of factors regulate the efficiency of
phosphate absorption in the intestine and phosphate
reabsorption in kidney. Apart from the well-known regu-
lators of phosphate homeostasis, namely parathyroid hor-
mone (PTH) and the vitamin D–endocrine system, a
number of peptides collectively known as the “phosphato-
nins” have been recently identified as a result of the study
of various diseases associated with hypophosphatemia.
These factors, fibroblast growth factor 23 (FGF-23),
secreted frizzled-related protein 4 (sFRP-4), fibroblast
growth factor 7 (FGF-7) and matrix extracellular phospho-
glycoprotein (MEPE), have been shown to play a role in the
pathogenesis of various hypophosphatemic and hyperphos-
phatemic disorders, such as oncogenic osteomalacia, X-
linked hypophosphatemic rickets, autosomal dominant
hypophosphatemic rickets, autosomal recessive hypophos-
phatemia and tumoral calcinosis. Whether these factors are
true hormones, in the sense that they are regulated by the
intake of dietary phosphorus and the needs of the organism
for higher or lower amounts of phosphorus, remains to be
firmly established in humans. Additionally, new informa-
tion demonstrates that the intestine “senses” luminal
concentrations of phosphate and regulates the excretion of
phosphate in the kidney by elaborating novel factors that
alter renal phosphate reabsorption.
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Phosphorus homeostasis
Phosphorus distribution: Phosphorus plays a critical role in
many biological processes, including energy metabolism,
cellular signaling through the phosphorylation of proteins
and other substances, nucleic acid metabolism, membrane
integrity, and bone mineralization. In the male human adult,
total body phosphorus is between 15 mol and 20 mol
(12.0 g/kg), the majority of which (80–90%) is present in
bone in the form of hydroxyapatite [1, 2]. The remainder is
present in soft tissues, extracellular fluid and erythrocytes.
Soft tissue phosphorus is between 0.1% and 0.3% wet
weight tissue (∼59 mmol/kg wet weight muscle). In plasma
or serum, phosphorus exists as inorganic phosphate, lipid
phosphorus and phosphoric ester phosphorus (concentra-
tions, in millimoles, of each being 0.71–1.36, 2.23–3.13
and 0.86–1.45, respectively). Clearly, the plasma compart-
ment contains only a small fraction of total body phospho-
rus, and changes in concentrations of inorganic phosphate
do not necessarily reflect total body stores of phosphorus.
Phosphorus homeostasis and its regulation: The amounts
of phosphorus moving across various epithelial tissues and
organs are depicted in Fig. 1 [3]. Phosphorus is absorbed in
the small intestine, predominantly in the jejunum, by both
transcellular and paracellular processes (Fig. 1), the former
process being mediated by sodium–phosphate type IIb
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phosphorus absorption in the intestine is dependent, in large
part, on the concentration of phosphorus present in the
intestinal lumen. Increasing amounts of dietary phosphorus
are associated with larger amounts of phosphorus absorp-
tion, with little evidence of saturation of the process. After
entering the extracellular fluid space and circulation,
phosphorus enters various tissues, including bone, as a
result, at least in part, of the activity of sodium–phosphate
type III cotransporters [4, 5]. Plasma inorganic phosphate is
filtered at the glomerulus and is reabsorbed in the proximal
tubule, largely via the sodium–phosphate cotransporter
type IIa [6].
The regulation of phosphorus homeostasis is a complex
process that involves the interplay between parathyroid
hormone and vitamin D endocrine system (Fig. 2)[ 3, 7].
Phosphorus balance is primarily determined by processes
that regulate the efficiency of intestinal phosphorus absorp-
tion and renal phosphorus reabsorption. Recent studies
have provided evidence that parathyroid hormone (PTH)
and vitamin D are not the sole regulators of inorganic
phosphate (Pi) homeostasis and have led to the identifica-
tion of other factors, such as the phosphatonins that
contribute to the maintenance of Pi homeostasis. In
addition, dietary Pi intake, dopamine, adrenergic activity
and blood pH also influence plasma Pi concentrations
Fig. 1 Phosphorus homeostasis
in humans. Reprinted with
permission [3]
Fig. 2 The interaction between
parathyroid hormone and vita-
min D–endocrine system in the
regulation of phosphorus
homeostasis
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that unique intestinal factors (“intestinal phosphatonins”),
released by increases in intestinal luminal phosphate
concentrations, alter the renal reabsorption of phosphate
(Figs. 4 and 5)[ 9]. It is likely that these intestinal
phosphatonins mediate the short-term changes in the
fractional excretion of phosphate observed after ingestion
of a meal, and it is likely that they play a role in the short-
term adaptation to changes in dietary phosphate. On the
other hand, long-term changes in dietary phosphate may be
associated with changes in PTH, 1,25-dihydroxyvitamin D
and the phosphatonins (see below).
The phosphatonins and disorders of phosphate homeostasis
in humans: The term “phosphatonin” was coined in 1994
to describe a circulating phosphaturic factor present in the
serum of patients with oncogenic or tumor-induced
osteomalacia (TIO) [10, 11]. Cai et al. described a patient
with TIO in whom the biochemical phenotype of hypo-
phosphatemia, renal phosphate wasting, reduced 1α,25-
dihydroxyvitamin D (1α,25(OH)2D) concentrations and the
osteomalacia resolved after removal of the tumor [10, 11].
X-linked hypophosphatemic rickets (XLH) [12], autosomal
dominant hypophosphatemic rickets (ADHR) [13], and
autosomal recessive hypophosphatemia (ARHP) [14] are
disorders that are phenotypically similar to TIO and which
demonstrate the presence of a circulating factor responsible
for hypophosphatemia and renal phosphate wasting [14–
17]. Conversely, concentrations of one of the phosphato-
nins, fibroblast growth factor 23, are reduced in patients
with tumoral calcinosis (TC), a disorder characterized by
hyperphosphatemia, reduced fractional excretion of phos-
phate and deposits of calcium phosphate in soft tissues [18–
24]. Several proteins, such as fibroblast growth factor-23
(FGF-23), secreted frizzled-related protein (sFRP-4), matrix
extracellular phosphoglycoprotein (MEPE) and fibroblast
growth factor-7 (FGF-7) have been identified as potential
phosphatonins and probably play a role in the pathogenesis
of some of these disorders [3, 14, 16, 17, 25–28]. Table 1
summarizes the pathophysiology of some of these hypo-
phosphatemic and hyperphosphatemic disorders. A more
detailed discussion of each of these peptides and their
physiology and pathophysiology follows.
The biology of phosphatonins
Fibroblast growth factor-23: FGF-23 is a secreted, circu-
lating, 32-kDa protein that is predominantly expressed in
osteocytes in the bone and in the endothelial cells that line
the venous sinusoids of bone marrow and the thymus [29].
Fig. 3 Factors regulating phosphorus homeostasis in humans (FGF
fibroblast growth factor, sFRP-4 secreted frizzled-related protein 4)
Fig. 4 Experimental evidence for the presence of intestinal
phosphatonins that mediate changes in renal phosphate excretion
following increases in luminal phosphate concentrations in the
intestine. Sodium phosphate (Na P) or sodium chloride (NaCl) was
infused into the duodena of rats, and fractional excretion (FE)o f
phosphate was measured at short intervals following the infusion
(TPTX thyroparathyroidectomized)
Fig. 5 Intestinal phosphatonins mediate changes in the renal
fractional excretion (FE) of phosphate following the ingestion of
meals containing increased amounts of phosphate (gray hatched
areas). Long-term dietary ingestion of increased amounts of phos-
phate is associated with increased PTH secretion and reduced 1,25-
dihydroxyvitamin D synthesis. The levels of phosphatonins (PTNs)
may increase following chronic increases in dietary phosphate
excretion in some experimental models. Excursions in the fractional
excretion of phosphate mediated by the intestinal phosphatonins still
occur in the presence of an elevated baseline fractional excretion of
phosphate. When phosphorus intake is curtailed, the opposite series of
events occurs
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elevated plasma Pi and 1α,25(OH)2D3 concentrations and
low PTH concentrations [30]. It is difficult to ascertain if
the decreased bone mineralization is a direct effect of
reduced FGF-23 or a consequence of elevated Pi and 1α,25
(OH)2D3 concentrations. Ectopic calcification in FGF-23
null mice is greatly diminished by either ablation of the
vitamin D receptor or by feeding the mice a low phosphate
diet, suggesting that elevated calcium and phosphate levels
are important in the formation of ectopic mineral deposits
[31, 32]. Transgenic mice over-expressing FGF-23 have
reduced plasma Pi concentration, phosphaturia and reduced
renal sodium phosphate cotransporter [33].
FGF-23 interacts with FGF receptors that belong to
type 1 transmembrane phosphotyrosine kinase receptors to
elicit a biological response in tissues [34]. Recent studies
indicate that FGF-23 also requires Klotho, as a co-factor for
receptor activation [34, 35]. In the mouse and human, the
klotho/Klotho gene encodes a single-pass membrane
protein which has homologies to β-glucosidases [36–39].
Two transcripts formed through alternative RNA splicing
are transcribed from the gene and encode a membrane or
secreted klotho protein [36]. A circulating and cerebrospi-
nal fluid (CSF) form of klotho is also formed as a result of
the cleavage of the membrane-bound form of the protein
[36, 40]. Klotho is expressed in several tissues, including
the kidney, reproductive tissues and brain [38]. The role of
Klotho as a FGF-23 co-receptor is supported by the fact
that Klotho-deficient mice have a phenotype similar to that
of FGF-23 null mice [37].
The presence of FGF-23 in the circulation of healthy
human subjects suggests that it plays a role in the
maintenance of Pi homeostasis. In humans, short-term
alterations in dietary Pi intake do not alter FGF-23 con-
centrations [41], and long-term changes in Pi intake have
modest or no effect on FGF-23 concentrations [42, 43]. In
animals FGF-23 concentrations are suppressed by low Pi
diets and are stimulated by high Pi diets [44, 45]. In the
short term, however, in rats there are no changes in FGF-23
or sFRP-4 concentrations following increases in intestinal
Pi [9]. Serum FGF-23 concentrations increase following the
administration of exogenous 1α,25(OH)2D3 [46], and FGF-
23 expression is increased in bone cells following 1α,25
(OH)2D3 treatment [47]. It is possible that the resultant
increase in serum Pi concentrations after the administration
of 1α,25(OH)2D3 stimulates the release of FGF-23, which,
in turn, reduces serum Pi by promoting phosphaturia
(Fig. 6). In hyperphosphatemic states, elevated Pi and
FGF-23 concentrations may jointly inhibit formation of
1α,25(OH)2D3.
Table 1 The pathophysiology of disorders of phosphate homeostasis associated with altered phosphatonin production/circulating concentrations
Clinical disorder Clinical phenotype Pathophysiology
Hypophosphatemic
disorders
Tumor-induced
osteomalacia (TIO)
Hypophosphatemia, hyperphosphaturia, reduced
1α,25(OH)2D concentrations or inappropriately
normal 1α,25(OH)2D concentrations for the
level of serum phosphate, osteomalacia
or mineralization defect
Excess of production of phosphatonins—FGF-23,
sFRP-4, MEPE, FGF-7 [10, 25, 50, 53, 78]
X-linked hypophosphatemic
rickets (XLH)
As in TIO Mutations in the endopeptidase PHEX that result
in increased concentrations of FGF-23, sFRP-4
and MEPE [29, 51, 58, 79]
Autosomal dominant
hypophosphatemic
rickets (ADHR)
As in TIO Mutations in the FGF-23 gene that result in the
formation of a mutant form of FGF-23 that is
resistant to proteolysis [16]
Autosomal recessive
hypophosphatemia
(ARHP)
As in TIO Mutations in the gene for DMP-1; associated with
elevated concentrations of FGF-23 [14, 17]
Hyperphosphatemic
disorders
Tumoral calcinosis Hyperphosphatemia, hypophosphaturia,
elevated or normal 1α,25(OH)2D
concentrations, ectopic calcification
Mutations in the genes for Ga1NAc transferase 3
(GALNT3), FGF-23, and Klotho [18–24, 67, 80].
Some patients with GALNT3 and FGF-23 mutations
have diminished concentrations of intact FGF-23.
The one patient with a Klotho mutation had very
high FGF-23 concentrations.
Renal failure Hyperphosphatemia, hypophosphaturia,
reduced 1α,25(OH)2D concentrations
Elevated FGF-23 and FGF-7 concentrations
1206 Pediatr Nephrol (2008) 23:1203–1210Secreted frizzled-related protein, fibroblast growth factor-7
and matrix extracellular phosphoglycoprotein: Like FGF-23,
sFRP-4 decreases renal Pi reabsorption by reducing
sodium phosphate transporters in renal proximal tubules
and inhibits formation of 1α,25(OH)2D3 [25]. FGF-7
inhibits sodium-dependent Pi transport in opossum kidney
cells, and anti-FGF-7 antibodies attenuate the phosphate
transport inhibition induced by FGF-7 [48]. We have
recently shown that FGF-7 is phosphaturic in vivo [49].
MEPE has been shown to increase the fractional excretion
of phosphate and to induce hypophosphatemia in vivo
[50]. In addition, MEPE inhibits bone mineralization in
vitro, and MEPE null mice have increased bone minerali-
zation. Importantly, MEPE does not inhibit 1α,25(OH)2D3
formation.
We will briefly discuss some clinical disorders in which
one or more of the phosphatonins play a key role in the
pathogenesis of the disease.
Role of phosphatonins in clinical disorders
Tumor-induced osteomalacia TIO is a syndrome due to the
presence of mesenchymal tumors that is associated with
hypophosphatemia, hyperphosphaturia, inappropriately low
serum 1α,25(OH)2D3 concentrations and osteomalacia
[10]. The resolution of these biochemical and bone
abnormalities following tumor removal supports the notion
of the presence of a circulating factor (phosphatonin)
secreted by the tumor. Numerous reports show elevation
of FGF-23 in some, but not all, patients with TIO [33, 51,
52]. Removal of the tumor is associated with reduction in
serum FGF-23 concentrations, and there is a temporal
association between reduction in FGF-23 concentration and
elevation in serum Pi, decrease in renal Pi wasting and
increase in 1α,25(OH)2D3 concentrations [33, 51, 52].
sFRP-4, MEPE and FGF-7 have also been shown to be
expressed by tumors associated with TIO [25, 48, 53]. The
presence of different phosphatonins in TIO points towards
the complex pathogenesis of this clinical condition.
X-linked hypophosphatemic rickets Patients with X-linked
hypophosphatemic rickets (XLH) manifest phosphaturia,
hypophosphatemia and rickets [12, 15, 54]. Parabiosis and
kidney cross-transplantation experiments have shown that
there is a circulating hypophosphatemic factor present in the
serum of Hyp mice (the mouse homolog of human XLH)
[55–57]. In XLH, there are mutations of the gene encoding
the endopeptidase, PHEX [15]. Patients with XLH have
elevated serum concentrations of FGF-23 [51, 58], thereby
indicating that PHEX is involved in the processing of FGF-
23. Some studies have demonstrated that PHEX is respon-
sible for FGF-23 degradation in vitro [26], whereas others
have failed to demonstrate such an effect [59–61].
Autosomal dominant hypophosphatemic rickets Autosomal
dominant hypophosphatemic rickets (ADHR) is an in-
herited disorder of Pi homeostasis characterized by phos-
phaturia, hypophosphatemia, osteomalacia and rickets [13].
The ADHR Consortium identified mutations in the FGF-23
gene that encodes a mutant FGF-23 protein that lacks a nor-
mal furin proconvertase site making it resistant to proteolysis
[16]. A long-lived stable form of FGF-23 is responsible for
the clinical manifestations of this disorder [62].
Fibrous dysplasia/McCune-Albright syndrome Fibrous dys-
plasia is a genetic non-inherited disease caused by somatic
activating missense mutations of GNAS 1 that lead to
variable clinical features, including polyostotic fibrous
dysplasia, with endocrine (precocious puberty, pituitary
gigantism, Cushing’s syndrome, thyrotoxicosis) and cuta-
neous (pigment patches on the skin) abnormalities [63]. Pi
wasting is seen in approximately 50% of these patients and
is associated with defective bone mineralization. One study
demonstrated that FGF-23 concentration was elevated in
patients with hypophosphatemia but was not increased in
patients with normal Pi concentrations [64]. It is possible
that the fibrous dysplastic tissue secretes FGF-23, and that
serum FGF-23 concentrations are reflective of the disease
burden in these patients.
Tumor calcinosis Patients with tumor calcinosis (TC)
manifest hyperphosphatemia, reduced renal Pi excretion
and elevated 1α,25(OH)2D3 concentrations [65]. Three
different types of mutations account for this syndrome.
The first type occurs in the gene Ga1NAc transferase 3
(GALNT3), which encodes a glycosyltransferase responsi-
ble for initiating mucin-type O-glycosylation [18]. Some
patients with this syndrome have low concentrations of
intact FGF-23 but high concentrations of FGF-23 frag-
ments. It has been hypothesized that these FGF-23 frag-
ments lack biological activity, and, therefore, the clinical
picture is consistent with what would be seen with low
intact FGF-23 concentrations. In vivo infusion studies with
Fig. 6 RelationshipsbetweenchangesinPi,1α,25(OH)2D and FGF-23.
Reprinted with permission [3]
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terminal fragments are biologically active [66]. At present,
there is uncertainty as to the precise mechanism by which
GALNT3 mutations cause the syndrome. The second class
of mutations responsible for TC occur in the gene encoding
FGF-23 [22, 24]. This mutation results in defective
processing of FGF-23 and its retention in the Golgi
apparatus. Failure to secrete FGF-23 results in low serum
concentrations of FGF-23, which, in turn, results in hyper-
phosphatemia due reduced renal Pi excretion. A third class
of mutations responsible for TC occurs in the gene for
Klotho [67], which encodes the co-receptor for FGF-23.
Renal failure Serum FGF-23 concentrations are elevated in
patients with chronic renal failure (CRF), and the increase
in FGF-23 correlates with the decline in glomerular
filtration rate [68–70]. Elevated plasma Pi seen in renal
failure could increase FGF-23 production, although it is
possible that reduced clearance of the peptide might also be
responsible. Whether or not the elevated serum FGF-23
concentrations found in chronic renal insufficiency are
sufficient to correct the hyperphosphatemia of early and
advanced CRF is not completely clear. Elevated FGF-23
could play a role in the suppression of 1,25(OH)2D
production and the development of secondary hyperparathy-
roidism. The role of FGF-23 in renal osteodystrophy has not
been established. Indeed, a recent study shows no effect of
FGF-23 on bone histology in end-stage renal disease [71].
Recently, Fliser et al. [72] showed a correlation between
increased FGF-23 concentrations and the progression of
chronic renal failure in subjects with mild-to-moderate
chronic renal disease, suggesting that FGF-23 may play a
role in the progression of renal failure. It should be noted,
however, that the number of other variables such as the
calcium X phosphate product, parathyroid hormone, and
vitamin D usage also correlated with progression in the
subjects. Finally, there are no data available at present
suggesting a direct role of FGF-23 on renal fibrogenesis.
Post-transplant hypophosphatemia In some patients fol-
lowing transplantation, persistent hypophosphatemia is
noted, despite relatively modest increases in concentrations
of circulating parathyroid hormone [68, 70, 73, 74].
In such subjects, FGF-23 concentrations have been noted
to be elevated, and it is possible that elevations in the
concentrations of this growth factor are responsible for the
hypophosphatemia seen in this situation.
Elevations in FGF-23 in patients with tumors In patients
with humoral hypercalcemia of malignancy, and with
metastatic ovarian cancer, FGF-23 concentrations are ele-
vated without significant hypophosphatemia [75–77]. This
would suggest that tumors produce FGF-23, and that FGF-
23 concentrations must reach a certain significant threshold
in order to increase phosphate excretion in the kidney.
In conclusion, phosphatonins play a vital role in the
pathogenesis of a wide array of disorders. The presence of
several phosphatonins and their differential effects affirm
the complexity of Pi regulation in both normal and disease
states. Future studies are needed to better understand the
role of these proteins.
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